Visão geral da empresa
Evaxion A/S operates as a clinical-stage biotechnology company dedicated to developing artificial intelligence-powered immunology vaccines designed to treat various malignancies. The enterprise functions within the broader healthcare sector, specifically the biotechnology industry, which is characterized by high research and development expenditures and reliance on successful clinical trial outcomes to achieve commercial viability. As of the latest data, the company maintains a total market capitalization of $34.28M, generates annual revenue of $7.53M, and employs a workforce of 46 individuals. These financial dimensions indicate that Evaxion A/S is a small-cap entity with limited scale relative to established pharmaceutical peers, suggesting that its current revenue base primarily reflects early-stage commercialization or licensing activities rather than mass-market sales. The combination of a market cap under $50 million and revenue below $10 million positions the company as an emerging player in the oncology landscape, where value is often derived from potential future approvals rather than current cash generation.
Saúde financeira
The company reported a trailing twelve-month revenue of $7.53M, a net income of -$7,707,000, and an EBITDA of -$8,873,000, highlighting a significant divergence between top-line sales and bottom-line profitability. The substantial gap between revenue and net income reveals a cost structure dominated by high operating expenses, likely associated with clinical trial costs, personnel salaries, and research infrastructure, which are typical for biotechnology firms in the development phase. Free cash flow stands at -$4,449,750, indicating that the company is consuming cash to fund its operations and development pipeline, which limits immediate financial flexibility but is a common characteristic of pre-revenue or early-revenue biotech companies. Gross margin is reported at 100.0%, suggesting that the company's cost of goods sold is negligible relative to its revenue, a common trait for companies that sell intellectual property or early-stage products without significant manufacturing overhead yet. Conversely, the operating margin is -122.7% and the profit margin is -102.4%, reflecting deep structural losses where operating expenses far exceed gross revenue, a situation expected during the clinical trial expansion phase. The balance sheet shows $23.23M in cash against $7.50M in debt, resulting in a debt-to-equity ratio of 44.04, which suggests a leveraged position relative to equity but one that is heavily cushioned by substantial cash reserves. The current ratio of 5.85 indicates a robust short-term liquidity position, as the company holds more than five times the value of its current liabilities in current assets. Return on equity is -100.2% and return on assets is -28.2%, metrics that reveal that management is currently generating negative returns on the capital invested, a standard metric for companies prioritizing growth and asset accumulation over immediate shareholder profit distribution.
Avaliação de valorização
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is calculated at 102.75, implying that the market prices the stock based on anticipated future profitability rather than current performance. The price-to-book ratio stands at 2.01, indicating that the market values the company at twice its book value, which suggests a premium assigned to the company's intangible assets, such as its intellectual property and clinical pipeline data. The price-to-sales ratio is 4.55, a multiple that is significantly higher than typical mature pharmaceutical firms, reflecting the high risk and high reward expectations inherent in clinical-stage biotechnology assets. Additionally, the EV/EBITDA multiple is -191.39, a negative figure that confirms the company's lack of earnings power in the current period and necessitates reliance on cash flow or asset backing for valuation. The stock has exhibited significant volatility, trading within a 52-week range between a high of $12.15 and a low of $1.20, with the current price situated well below the recent peak. The beta coefficient is 0.20, indicating that the stock's price volatility is substantially lower than the broader market, suggesting it may act as a defensive position or a low-correlation asset during broader market fluctuations.
Growth & Income
Revenue growth year-over-year is recorded at -100.0%, while earnings growth is N/A, indicating a complete contraction in revenue and the absence of positive earnings trajectory to compare against. The negative revenue growth rate suggests that the company may be transitioning from a previous revenue model, potentially shifting focus entirely to clinical development costs rather than commercial sales volume. As the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings are theoretically reinvested into the business, though current losses preclude any meaningful reinvestment of profit. Since the company generates negative free cash flow and net income, it cannot sustain a dividend payout, and the zero payout ratio confirms that shareholder returns are currently derived solely from capital appreciation potential rather than income distributions. The overall growth and income profile is defined by negative revenue expansion and zero dividend distribution, reflecting a strategic focus on long-term product development rather than short-term profitability or income generation.